Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

FDA delays decision on extending Yutrepia to treat PH-ILD

Note: This story was updated Jan. 30, 2024, to correct the approved indications of available treprostinil formulations. The U.S. Food and Drug Administration (FDA) has delayed its decision to extend the use of Yutrepia — Liquidia‘s inhaled dry powder formulation of treprostinil — to people with…

Widening of the pulmonary artery in PH is common: Large-scale study

Pulmonary arterial dilatation — the abnormal widening of the main pulmonary artery leading from the heart — was a common feature among people with pulmonary hypertension (PH) in a large-scale study. The clinical characteristics related to a dilated pulmonary artery, such as heart function and blood flow parameters, varied widely…

Early study of inhaled nitric oxide delivery system doses 1st patient

An early feasibility study evaluating Third Pole Therapeutics‘ eNOfit — a miniaturized, portable inhaled nitric oxide (iNO) delivery system to treat pulmonary hypertension (PH) associated with interstitial lung disease — has dosed its first patient, the company announced. The goal for the investigational device is to provide patients…

HDL component ApoA-I predicts mortality in PAH: Study

Lower levels of apolipoprotein A-I (ApoA-I), a component of high-density lipoprotein (HDL), or “good cholesterol,” is a significant predictor of mortality in people with pulmonary arterial hypertension (PAH), a study suggests. “Our study identified the significance of ApoA-I as a biomarker for predicting the survival outcome of PAH patients,”…

PH has no effect on mortality in heart transplant: Study

The presence of pulmonary hypertension (PH) didn’t increase mortality after a heart transplant, according to a new study. The findings oppose earlier studies that suggested an increased mortality rate among transplant recipients with PH, which was considered a contraindication. A secondary analysis of a large transplant registry with 24…

AI Therapeutics begins dosing in Phase 2 trial of LAM-001

AI Therapeutics has begun dosing in a clinical trial testing inhaled LAM-001, a potential disease-modifying therapy for pulmonary arterial hypertension (PAH). The 24-week, open-label Phase 2 study (NCT05798923) is recruiting 15 adults at Brigham and Women’s Hospital in Boston, Massachusetts. All participants should have advanced PAH…

Balloon pulmonary angioplasty can pose risks for CTEPH patients

Older age and high blood pressure in the pulmonary arteries raise the risk of complications with balloon pulmonary angioplasty (BPA), a second-line treatment for chronic thromboembolic pulmonary hypertension (CTEPH), a study suggested. If high blood pressure persists after surgery to remove the pulmonary arterial blood clots that cause…


A Conversation With Rare Disease Advocates